MANTLE CELL LYMPHOMA — A CHALLENGING DISEASE.
POOR PROGNOSIS AT INITIAL DIAGNOSIS
|
|
Combines unfavorable clinical features of both indolent and aggressive lymphomas8
|
|
|
Rapid disease progression8
|
|
|
Median survival is approximately 3 years from diagnosis, among the shortest of
lymphoma subtypes10-13
|
Adapted from Fisher et al, from a review determining the clinical presentation and natural history of MCL.
FOLLOWING CHEMOTHERAPY, PATIENTS COMMONLY RELAPSE
|
|
In the relapsed setting, durable complete and partial responses to multi-agent chemotherapy
are uncommon8,12
|
|
|
Median survival after first relapse is estimated to be 1 to 2 years8,10
|
VELCADE® is indicated for the treatment of patients with mantle cell lymphoma who have received at least
one prior therapy. VELCADE is contraindicated in patients with hypersensitivity to bortezomib, boron, or
mannitol. VELCADE should be administered under the supervision of a physician experienced in the use of
antineoplastic therapy.
Please
click here to view additional important safety information.
For full Prescribing Information
click here. (pdf) (74KB)
For further information about VELCADE® (bortezomib) for Injection, call 1-866-VELCADE (U.S. clinicians only).
